Skip to main content
Fig. 3 | Virology Journal

Fig. 3

From: Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants

Fig. 3

Effect of SKAI-DS84 on authentic virus neutralization. Dose-dependent effects of SKAI-DS84 on SARS-CoV-2 variant (B.1.617.2 and B.1.1.529) neutralization. a Crystal violet staining data obtained by measuring the TCID50 in authentic virus-infected VeroE6 cells treated with increasing concentrations of SKAI-DS84 for 72 h. b Dose–response graphs generated by measuring the relative SARS-CoV-2 and GAPDH RNA levels using RT-qPCR analyses of either B.1.617.2- or B.1.1.529-infected VeroE6 cells treated with increasing concentrations of SKAI-DS84 for 72 h. c The in vitro ADE assay was performed as described in Raji (FcγR II-dependent) and U973 (FcγR I&II-dependent) cells. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ADE, antibody-dependent enhancement; TCID50, tissue culture infective dose. *P < 0.05, **P < 0.01, significantly different from control

Back to article page

Virology Journal

ISSN: 1743-422X